Mirum Pharmaceuticals (MIRM) Liabilities and Shareholders Equity (2018 - 2026)

Mirum Pharmaceuticals' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $890.9 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 29.07% year-over-year to $890.9 million; the TTM figure through Mar 2026 stood at $3.2 billion (up 20.64% YoY), while the FY2025 annual figure was $842.8 million, up 25.65% from the prior year.
• Liabilities and Shareholders Equity was $890.9 million for Q1 2026 at Mirum Pharmaceuticals, up from $842.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $890.9 million in Q1 2026 to a low of $278.1 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $585.5 million across 5 years, with a median of $652.0 million in 2024.
• Biggest YoY gain for Liabilities and Shareholders Equity was 95.47% in 2024; the steepest drop was 2.65% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $352.9 million in 2022, then soared by 83.23% to $646.6 million in 2023, then advanced by 3.73% to $670.8 million in 2024, then increased by 25.65% to $842.8 million in 2025, then advanced by 5.71% to $890.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $890.9 million (Q1 2026), $842.8 million (Q4 2025), and $785.1 million (Q3 2025), per Business Quant data.